Testing Robustness of Child STEPs Effects with Children and Adolescents: A Randomized Controlled Effectiveness Trial.

Published online

Journal Article

A critical task in psychotherapy research is identifying the conditions within which treatment benefits can be replicated and outside of which those benefits are reduced. We tested the robustness of beneficial effects found in two previous trials of the modular Child STEPs treatment program for youth anxiety, depression, trauma, and conduct problems. We conducted a randomized trial, with two significant methodological changes from previous trials: (a) shifting from cluster- to person-level randomization, and (b) shifting from individual to more clinically feasible group-based consultation with STEPs therapists. Fifty community clinicians from multiple outpatient clinics were randomly assigned to receive training and consultation in STEPs (n = 25) or to provide usual care (UC; n = 25). There were 156 referred youths-ages 6-16 (M = 10.52, SD = 2.53); 48.1% male; 79.5% Caucasian, 12.8% multiracial, 4.5% Black, 1.9% Latino, 1.3% Other-who were randomized to STEPs (n = 77) or UC (n = 79). Following previous STEPs trials, outcome measures included parent- and youth-reported internalizing, externalizing, total, and idiographic top problems, with repeated measures collected weekly during treatment and longer term over 2 years. Participants in both groups showed statistically significant improvement on all measures, leading to clinically meaningful problem reductions. However, in contrast to previous trials, STEPs was not superior to UC on any measure. As with virtually all treatments, the benefits of STEPs may depend on the conditions-for example, of study design and implementation support-in which it is tested. Identifying those conditions may help guide appropriate use of STEPs, and other treatments, in the future.

Full Text

Duke Authors

Cited Authors

  • Weisz, JR; Bearman, SK; Ugueto, AM; Herren, JA; Evans, SC; Cheron, DM; Alleyne, AR; Weissman, AS; Tweed, JL; Pollack, AA; Langer, DA; Southam-Gerow, MA; Wells, KC; Jensen-Doss, A

Published Date

  • September 13, 2019

Published In

Start / End Page

  • 1 - 14

PubMed ID

  • 31517543

Pubmed Central ID

  • 31517543

Electronic International Standard Serial Number (EISSN)

  • 1537-4424

Digital Object Identifier (DOI)

  • 10.1080/15374416.2019.1655757

Language

  • eng

Conference Location

  • England